Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Chemotherapy-Minimized Blank Microsphere Transarterial Embolization (BMS-TACE) in Hepatocellular Carcinoma Resistant to FOLFOX-Based Hepatic Arterial Infusion Chemotherapy

15 de noviembre de 2026 actualizado por: Huang Jinhua, Sun Yat-sen University

Chemotherapy-Minimized, Blank Microsphere-Based Transarterial Chemoembolization (BMS-TACE) in Patients With BCLC Stage B/C Hepatocellular Carcinoma Resistant to FOLFOX-Based Hepatic Arterial Infusion Chemotherapy: A Single-Center, Single-Arm, Phase 2 Trial

FOLFOX-based hepatic arterial infusion chemotherapy (HAIC) is widely used for advanced hepatocellular carcinoma (HCC) in China, yet many patients show primary resistance or progress after an initial response, and no prospective trial has defined the optimal salvage strategy. This single-center, single-arm, phase 2 trial evaluates the efficacy and safety of chemotherapy-minimized, blank microsphere-based transarterial chemoembolization (BMS-TACE) in patients with BCLC stage B/C HCC resistant to FOLFOX-HAIC. In BMS-TACE, blank microspheres are the principal embolic agent and chemotherapy is used only as an adjunct at a minimal dose (low-dose pirarubicin in a small volume of lipiodol), in order to limit chemotherapy-related liver injury and systemic toxicity and to allow repeated embolization in patients with limited hepatic reserve. Forty-three participants will be enrolled using a Simon two-stage design. The primary endpoint is objective response rate by investigator assessment using mRECIST.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

43

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Jinhua Huang, MD, PhD
  • Número de teléfono: 0086-20-87343447
  • Correo electrónico: huangjh@sysucc.org.cn

Ubicaciones de estudio

    • Guangdong
      • Guangzhou, Guangdong, Porcelana, 510060
        • Reclutamiento
        • Sun Yat-sen University Cancer Center
        • Contacto:
          • Jinhua Huang, MD, PhD
          • Número de teléfono: 0086-20-87343447
          • Correo electrónico: huangjh@sysucc.org.cn

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Written informed consent
  • Age 18-75 years, any sex
  • Hepatocellular carcinoma confirmed by histology or cytology, or diagnosed clinically according to AASLD criteria
  • BCLC stage C, or BCLC stage B beyond the up-to-seven criteria
  • At least 4 prior cycles of FOLFOX-based hepatic arterial infusion chemotherapy (HAIC), with stable disease or progressive disease per RECIST 1.1 on contrast-enhanced CT or MRI performed 1-3 months after the last HAIC cycle
  • Portal vein, hepatic vein or inferior vena cava tumor thrombus and distant metastasis are permitted
  • Not a candidate for surgical resection as judged by the treating physician
  • Child-Pugh score ≤ 7
  • ECOG performance status 0-1
  • Adequate bone marrow function: absolute neutrophil count ≥ 1.5 × 10^9/L; hemoglobin ≥ 70 g/L; platelet count ≥ 50 × 10^9/L; white blood cell count ≥ 3.0 × 10^9/L
  • Adequate hepatic function: serum albumin ≥ 28 g/L; total bilirubin ≤ 3.0 mg/dL; AST and ALT ≤ 5 × upper limit of normal (ULN)
  • Adequate renal function: serum creatinine ≤ 1.5 × ULN
  • Adequate coagulation (not on anticoagulants): INR ≤ 2.3
  • Active hepatitis B virus infection: on antiviral therapy per local standard of care and willing to continue during the study
  • Hepatitis C virus antibody positive: on antiviral therapy per local standard of care and willing to continue during the study

Exclusion Criteria:

  • History of hypersensitivity or intolerance to any agent used in the study
  • Uncontrolled clinically significant ascites (not controlled by diuretics or paracentesis)
  • History of hepatic encephalopathy
  • Clinically significant gastrointestinal bleeding within 30 days before enrollment, or variceal bleeding within the past 3 months
  • Uncorrectable coagulopathy or marked hematological abnormality with evident bleeding tendency
  • Significant cardiovascular disease: congestive heart failure of NYHA class II or higher, unstable angina, myocardial infarction, or arrhythmia requiring medical treatment
  • History of congenital long QT syndrome, or corrected QT interval > 480 ms (Fridericia)
  • Left ventricular ejection fraction < 45%
  • Inadequately controlled hypertension (systolic > 150 mmHg and/or diastolic > 100 mmHg)
  • Urine protein ≥ 1 g/24 h (24-hour urine collection required if dipstick ≥ 1+)
  • Prior organ transplantation
  • Gastrointestinal malabsorption or any other condition that in the investigator's opinion may affect drug absorption
  • Active infection other than HBV or HCV
  • Other malignancy within the past 3 years or concurrent malignancy
  • Any other condition that in the investigator's opinion makes the patient unsuitable for the study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: BMS-TACE

All participants receive chemotherapy-minimized, blank microsphere-based transarterial chemoembolization (BMS-TACE). Retreatment is performed on demand according to imaging every 6 weeks until progression, unacceptable toxicity, technical infeasibility, or withdrawal. Participants who were receiving anti-angiogenic therapy plus a PD-1/PD-L1 inhibitor concurrently with FOLFOX-HAIC continue the same regimen unchanged; participants who received FOLFOX-HAIC without systemic therapy do not start systemic therapy during the study. Other locoregional treatments (ablation, seed implantation) are not permitted unless the tumor is downstaged to allow curative treatment.

Visceral angiography of the celiac trunk, superior mesenteric artery and phrenic arteries maps the arterial supply of the tumor. A 2.8F microcatheter is placed super-selectively into each tumor-feeding artery by coaxial technique. A minimal-dose chemoemulsion (low-dose pirarubicin in a small volume of lipiodol) is injected first. Blank microspheres of any manufacturer are then delivered in ascending size order: 40-120 microns mixed with 5 mL contrast to occlude the distal tumor arterial bed; 100-300 microns for tumor arterial branches, with supplementary lipiodol emulsion if vascular lakes are seen; then 300-500 or 500-700 microns for the main feeding trunk. The endpoint is contrast stasis over 3-5 cardiac cycles with loss of at least 90% of intrahepatic tumor staining on completion angiography. Imaging is repeated every 6 weeks; retreatment follows protocol-defined criteria. Performed by one of two designated interventional radiologists.

Otros nombres:
  • bTACE
  • Blank microsphere embolization with low-dose chemotherapy

Low-dose pirarubicin emulsified with a small volume of lipiodol and injected intra-arterially into the tumor-feeding artery immediately before blank microsphere embolization, as the minimal-dose chemotherapy adjunct of each BMS-TACE session.

Otros nombres:
  • THP
  • Tetrahydropyranyl-adriamycin

Calibrated blank (non-drug-loaded) microspheres, 40-120, 100-300, 300-500 and 500-700 microns, of any manufacturer, delivered in ascending size order as the principal embolic agent in BMS-TACE.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Objective Response Rate (ORR) Per Modified Response Evaluation Criteria in Solid Tumors (mRECIST) as Assessed by Investigator
Periodo de tiempo: From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)

ORR is defined as the proportion of participants whose best overall response from enrollment (first BMS-TACE) is complete response (CR) or partial response (PR) per mRECIST, as assessed by the investigator together with a senior radiologist. Tumor assessment by contrast-enhanced CT or MRI is performed after the first BMS-TACE and every 6 weeks (±7 days) thereafter, regardless of treatment delays, until progression, unacceptable toxicity, death, withdrawal of consent, loss to follow-up or study termination. Analysis population: full analysis set (all enrolled participants); participants without post-baseline assessment are counted as non-responders.

From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Progression-Free Survival (PFS) Per mRECIST as Assessed by Investigator
Periodo de tiempo: From enrollment until progression or death (up to approximately 30 months)

PFS is defined as the time from enrollment (first BMS-TACE) to the first documented radiological progression per mRECIST or death from any cause, whichever occurs first. Participants alive without progression are censored at the date of last tumor assessment. Estimated by the Kaplan-Meier method.

From enrollment until progression or death (up to approximately 30 months)
Disease Control Rate (DCR) Per mRECIST as Assessed by Investigator
Periodo de tiempo: From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)

Proportion of participants whose best overall response is CR, PR or stable disease (SD) per mRECIST, using the same assessment schedule as the primary outcome.

From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)
Duration of Response (DOR) Per mRECIST as Assessed by Investigator
Periodo de tiempo: From first documented response until progression or death (up to approximately 30 months)

Among responders, the time from first documented CR or PR to first documented progression per mRECIST or death from any cause, whichever occurs first; responders without progression or death are censored at the last tumor assessment.

From first documented response until progression or death (up to approximately 30 months)
Overall Survival (OS)
Periodo de tiempo: From enrollment until death from any cause (up to approximately 30 months)

OS is defined as the time from enrollment to death from any cause. Participants alive at last contact are censored at the date of last follow-up. Survival follow-up every 12 weeks (±7 days) after progression or start of new anticancer therapy, continuing until at least 12 months after the last participant's first BMS-TACE.

From enrollment until death from any cause (up to approximately 30 months)
Time to Untreatable Progression (TTUP)
Periodo de tiempo: From enrollment until untreatable progression (up to approximately 30 months)

Time from enrollment to progression that precludes further BMS-TACE, including untreatable tumor progression and deterioration of liver function to Child-Pugh class C, as judged by the investigator. Participants still eligible for BMS-TACE are censored at last assessment.

From enrollment until untreatable progression (up to approximately 30 months)
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by Investigator
Periodo de tiempo: From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)

Sensitivity analysis of the primary endpoint: proportion of participants with best overall response of CR or PR per RECIST 1.1, using the same assessment schedule.

From first BMS-TACE until disease progression, assessed after the first BMS-TACE and every 6 weeks thereafter (up to approximately 12 months)
Incidence and Severity of Adverse Events Per NCI CTCAE Version 5.0
Periodo de tiempo: From first BMS-TACE until 30 days after last BMS-TACE (up to approximately 13 months)

Number and proportion of participants with treatment-emergent adverse events, serious adverse events and treatment-related adverse events, graded per NCI CTCAE v5.0, from first BMS-TACE until 30 days after the last BMS-TACE or start of new anticancer therapy, whichever is first. Safety set: all participants who receive at least one BMS-TACE.

From first BMS-TACE until 30 days after last BMS-TACE (up to approximately 13 months)

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Change From Baseline in Quality of Life Per EORTC QLQ-C30
Periodo de tiempo: Baseline, every 6 weeks during treatment, and end of treatment (up to approximately 12 months)

Change from baseline in health-related quality of life assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Scores for the global health status/quality of life scale, the five functional scales, and the symptom scales/items are linearly transformed to range from 0 to 100. Higher global health status/quality of life and functional scores indicate better quality of life or functioning; higher symptom scores indicate worse symptoms/problems. Change from baseline is calculated separately for each scale/item as the post-baseline score minus the baseline score.

Baseline, every 6 weeks during treatment, and end of treatment (up to approximately 12 months)
Change From Baseline in Quality of Life Per EORTC QLQ-HCC18
Periodo de tiempo: Baseline, every 6 weeks during treatment, and end of treatment (up to approximately 12 months)

Change from baseline assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Hepatocellular Carcinoma Module (EORTC QLQ-HCC18). This 18-item module assesses fatigue, body image, jaundice, nutrition, pain, fever, abdominal swelling, and sexual interest. Each scale/item score is linearly transformed to range from 0 to 100; higher scores indicate worse symptoms/problems or poorer health-related quality of life. Change from baseline is calculated separately for each scale/item as the post-baseline score minus the baseline score.

Baseline, every 6 weeks during treatment, and end of treatment (up to approximately 12 months)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Jinhua Huang, MD, PhD, Sun Yat-Sen University Cancer Center
  • Director de estudio: Zhimei Huang, MD, Sun Yat-Sen University Cancer Center

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

20 de octubre de 2026

Finalización primaria (Estimado)

1 de octubre de 2028

Finalización del estudio (Estimado)

1 de marzo de 2029

Fechas de registro del estudio

Enviado por primera vez

9 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

15 de noviembre de 2026

Publicado por primera vez (Actual)

19 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

15 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • SL-B2025-858-02

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .